Clinical Trial Update: Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing karenitecin to topotecan in advanced epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Karenitecin
• Topotecan (topotecan)

Snippet

Sponsor: BioNumerik Pharmaceuticals, Inc. | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED